Press Releases
Category: Press Releases 29 November 2022
Sprachpate bei Kitakindern
Die "Berliner Zeitung" berichtet über Matthias Bräutigams ehrenamtliche Tätigkeit als Sprachpate für Berliner Kinder, die Sprachschwierigkeiten haben.
Was Sprachpaten mit Kitakindern erleben: „Er war wie in einer Schockstarre“
Category: Press Releases 21 January 2022
Angriff auf das zelluläre Netzwerk von Krebs - Neue Option für die Entwicklung wirksamer Therapien bei Lungenkrebs?
Die Behandlung von Patienten mit fortgeschrittenem Lungenkrebs stellt trotz wesentlicher Fortschritte nach wie vor eine große medizinische Herausforderung dar. Die zur Verfügung stehenden Therapieoptionen bedeuten in der Regel zwar eine Verlängerung der Lebenszeit können aber die tödliche Krankheit in den meisten Fällen nur für einen begrenzten Zeitraum aufhalten.
Category: Press Releases 19 November 2021
Dr Ulrike Lorch joins the leadership team at the Faculty of Human Pharmacology
Richmond Pharmacology’s Medical Director, Dr Ulrike Lorch, has been appointed Director of Human Pharmacology for the Faculty of Pharmaceutical Management (FPM).
Category: Press Releases 25 October 2021
Dr Taubel discusses the future of new medicine development and first-in-human studies
In a recent article for PMLiVE and Pharmaceutical Market Europe, Dr Jorg Taubel, CEO of Richmond Pharmacology, outlines the future of new medicine development, influenced by the emergence of gene-based therapies and the reshaping of the way first-in-human clinical studies are delivered.
Category: Press Releases 6 July 2021
Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021. Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.
Category: COVID-19 21 April 2021
Richmond Research Institute asks the question, 'Do post-COVID-19 patients need a second dose of vaccine?'
Richmond Research Institute is actively involved in COVID-19 symptoms testing for all staff and visitors who attempt entry to Richmond Pharmacology's London bridge clinical trial unit. The data accumulated throughout this period before and after vaccination has led to the following publication: 'Do post-COVID-19 patients need a second dose of vaccine?
Category: Press Releases 11 April 2021
Accelero contributes tp CombiGene AB’s Gene Therapy Program for Epilepsy
Accelero is proud becoming a selected partner for the leading Nordic gene therapy company CombiGene AB (Lund) developing an AAV-based treatment targeting epilepsy.
Category: Press Releases 19 February 2021
Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy
Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.
Category: Press Releases 10 November 2020
Marking a milestone for gene editing
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001.
Category: COVID-19 8 April 2020
Management of pulmonary Imaging in clinical research during the COVID-19 crisis
Trialists, researchers, investigators and sponsors: you will need to manage all those lung images in all emerging COVID-19 research and in many ongoing clinical trials. Pharmtrace, a member of Conelis e.V. offers a GCP and privacy-compliant online image management platform which is ready to go. For all academic networks fighting the COVID-19 pandemia, the service will be offered for free.
http://pharmtrace.com/en/image-management/pharmtrace-supports-covid-19-research/